A cancer patient died and four others spent time in hospital after a pharmaceutical company gave them "unlicensed" chemotherapy medicine.
The health watchdog has now launched a probe as Sciensus, which provides treatment to around 200,000 in the UK, admitted the blunder. An unlicensed version of prostate cancer medicine cabazitaxel was given to four patients, including the one who later died.
The patients have not been named, nor have any further details, including their ages and where they lived, been disclosed at this stage. The three other patients were treated in hospital in April, it has today emerged.
